Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade—a worldwide perspective
Inserm · Université Paris Cité · +12 more institutions
Abstract
Immune-checkpoint inhibitors (ICI) have revolutionized cancer treatment by harnessing the immune system but ICI can induce life-threatening immune-related adverse events (irAE) affecting every organ.
We extracted irAE from VigiBase, the international pharmacovigilance database, first reported in 2008 until 01/2023 to characterize irAE reporting trends, clinical features, risk factors and outcomes.
Citation impact
- FWCI
- 29.30
- Percentile
- 100%
- References
- 38
Authors
13- PGPaul Gougis
Inserm, Université Paris Cité, Sorbonne Université, Assistance Publique – Hôpitaux de Paris, Immunité et Cancer, Pitié-Salpêtrière Hospital
- FJFloriane Jochum
Inserm, Université Paris Cité, Immunité et Cancer, Hôpitaux Universitaires de Strasbourg, Université de Strasbourg
- BABaptiste Abbar
Inserm, Sorbonne Université, Assistance Publique – Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Centre d'Immunologie et des Maladies Infectieuses
- ÉDÉlise Dumas
Inserm, Université Paris Cité, Immunité et Cancer
- KBKévin Bihan
Inserm, Sorbonne Université, Assistance Publique – Hôpitaux de Paris, Pitié-Salpêtrière Hospital
Topics & keywords
- Medicine
- Pneumonitis
- Adverse effect
- Cancer
- Internal medicine
- Myasthenia gravis
- Nivolumab
- Ipilimumab
- Zero hunger